BioNTech SE (NASDAQ:BNTX – Get Free Report)’s share price gapped down before the market opened on Friday after JPMorgan Chase & Co. lowered their price target on the stock from $94.00 to $91.00. The stock had previously closed at $87.25, but opened at $84.25. JPMorgan Chase & Co. currently has an underweight rating on the stock. BioNTech shares last traded at $84.75, with a volume of 199,122 shares.
A number of other analysts have also commented on the stock. Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. HC Wainwright restated a “buy” rating and set a $113.00 price objective on shares of BioNTech in a research note on Thursday, August 1st. TD Cowen lowered their target price on BioNTech from $98.00 to $85.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th. HSBC upgraded BioNTech from a “hold” rating to a “buy” rating in a report on Friday, August 2nd. Finally, Evercore ISI started coverage on BioNTech in a research report on Tuesday, May 14th. They set an “inline” rating and a $100.00 price target on the stock. One analyst has rated the stock with a sell rating, five have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $109.09.
Institutional Investors Weigh In On BioNTech
A number of large investors have recently added to or reduced their stakes in the business. Harding Loevner LP bought a new stake in BioNTech in the 4th quarter valued at about $410,984,000. Candriam S.C.A. lifted its stake in BioNTech by 261.2% during the second quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after purchasing an additional 418,695 shares during the last quarter. Point72 Asset Management L.P. grew its position in BioNTech by 283.5% in the second quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock valued at $37,103,000 after acquiring an additional 341,311 shares during the last quarter. Primecap Management Co. CA boosted its stake in shares of BioNTech by 2.8% in the 4th quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock valued at $502,735,000 after purchasing an additional 131,490 shares in the last quarter. Finally, abrdn plc bought a new stake in shares of BioNTech during the 4th quarter valued at approximately $10,961,000. Institutional investors own 15.52% of the company’s stock.
BioNTech Stock Performance
The firm has a market capitalization of $20.25 billion, a price-to-earnings ratio of 170.38 and a beta of 0.23. The company has a current ratio of 11.38, a quick ratio of 11.16 and a debt-to-equity ratio of 0.01. The stock’s 50-day moving average is $84.68 and its 200-day moving average is $89.76.
BioNTech (NASDAQ:BNTX – Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). The firm had revenue of $128.70 million during the quarter, compared to the consensus estimate of $134.98 million. BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The firm’s revenue was down 23.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.86) earnings per share. On average, analysts predict that BioNTech SE will post -2.04 EPS for the current fiscal year.
BioNTech Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.